Gains and losses of CD44 expression during breast carcinogenesis and tumour progression

Bànkfalvi, Àgnes; Hj, Terpe; Breukelmann, Dirk; Bier, Bert; Rempe, David A.; Pschadka, G; Krech, Rainer; Böcker, W.

doi:10.1046/j.1365-2559.1998.00472.x

Cited by 63 publications

(62 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This indicates alternative pathways in breast carcinogenesis, as reflected by recent cytogenetic and adhesion molecule studies from our group, as well. 41,42 We conclude that in both the normal breast and benign proliferative breast diseases, there is a heterogeneous proliferation of progenitor, glandular, and myoepithelial cells as well as their intermediary antecedents in different proportions. In contrast, intraductal neoplastic breast lesions (atypical ductal hyperplasia and ductal carcinoma in situ non-high grade), are composed of one proliferating cell type, namely malignantly transformed glandular epithelial cells.…”

Section: Discussionmentioning

confidence: 86%

Different proliferative activity of the glandular and myoepithelial lineages in benign proliferative and early malignant breast diseases

et al. 2004

View full text Add to dashboard Cite

The aim of the present study was to explore cell biological characteristics of normal breast, benign proliferative breast diseases and noninvasive breast malignancies based on the recently published adult progenitor cell concept from our group. Here, we investigated the proliferative activity of CK5/14 þ , CK8/18/19 þ and a-smooth muscle actin þ cellular phenotypes encountered in normal mammary gland, in a series of usual ductal hyperplasias and early malignant breast diseases, such as atypical ductal and lobular hyperplasias, as well as ductal and lobular in situ carcinomas. Immunohistochemical double labeling was performed on frozen sections from diagnostic breast biopsies by using antibodies to basal cytokeratins (CK5/14), glandular cytokeratins (CK8/18/19), smooth muscle actin and the Ki-67 antigen (MIB1). Normal breast tissues and usual ductal hyperplasias were characterized by a heterogeneous cellular composition of the growth fraction. The proliferative cell compartment consisted of CK8/18/19 þ glandular and, in a variable proportion, CK5/14 þ progenitor phenotypes. In contrast, noninvasive breast malignancies were composed of a monotonous proliferation of CK 8/18/19 þ neoplastic glandular cells. These findings indicate a significant role of progenitor cells in the development of benign proliferative breast diseases and lend support to the view that malignant transformation in the human breast usually occurs in a cell committed to the glandular lineage. Our results provide cell kinetic support to the functional progenitor cell hypothesis, and we propose this concept as an operative model for understanding benign proliferative and malignant breast diseases.

show abstract

Section: Discussionmentioning

confidence: 86%

Different proliferative activity of the glandular and myoepithelial lineages in benign proliferative and early malignant breast diseases

et al. 2004

View full text Add to dashboard Cite

show abstract

“…HER2-negative is part of the basal phenotype. Bànkfalvi et al indicated that myoepithelial cells expressed CD44 in normal breast epithelium, and that this is implicated in the early stage of breast carcinogenesis (21). Herrera-Gayol et al observed that CD44 expression was involved in two of the three steps of the invasive cascade and could not be confidently used as a reliable prognostic indicator (22).…”

Section: Discussionmentioning

confidence: 99%

“…Sanchez et al revealed a deregulation in the CD44 expression pattern in malignant tumors, but did not identify a correlation between this deregulation and clinicopathological factors (23). Conversely, Bànkfalvi et al observed that increased levels of CD44 expression were correlated with poor prognosis and metastatic involvement of the axillary lymph nodes in breast cancer (21). Looi et al revealed that CD44 played a role in the progression of breast cancer (24).…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer

et al. 2016

View full text Add to dashboard Cite

Abstract.A subpopulation of breast cancer cells with cluster of differentiation (CD)44-positive and CD24-negative expression has been reported to have stem cell properties and to have a higher tumorigenic capacity than other cells. However, the clinico pathological characteristics of this subpopulation are not fully understood. In this study, we aimed to identify the correlations between the expression of CD44 and CD24 and clinicopathological parameters and overall survival. We studied specimens from 262 patients with invasive breast cancer. Immunohistochemical staining for CD44 and CD24 was performed using tissue microarrays. The clinico pathological factors were evaluated from the patients' medical records. In correlation analysis, CD44 expression was significantly associated with human epidermal growth factor receptor 2 (HER2)-negative status (P<0.001). Conversely, CD24 expression was significantly associated with HER2-positive status (P<0.001). CD44 and CD24 expression did not demonstrate any correlation with the age, tumor size, axillary lymph node metastasis status, tumor stage, histological grade, estrogen receptor status and progesterone receptor status of patients. Upon survival analysis, there was no statistical difference in overall survival according to the expression of CD44 and CD24. The results from this study suggest that CD44 and CD24 are clinically significant markers associated with breast tumorigenesis, but not sufficient factors in determining the prognosis of invasive breast cancer.

show abstract

“…Moreover, HA is clearly involved in cellular motility by virtue of its ability to form a pericellular sheath in combination with aggregating proteoglycans such as versican and aggrecan (12). Although the sheath is anchored by HA-receptors such as CD44, which have themselves been associated with outcome in breast cancer (29), the existence of sheath relies on its aggregating proteoglycan content (30). 8 To clarify the independent roles of HA and versican, in vitro studies need to be performed to determine whether versican promotes motility and invasion of breast cancer cells in the absence of a pericellular sheath of HA.…”

Section: Discussionmentioning

confidence: 99%

Expression of Extracellular Matrix Components Versican, Chondroitin Sulfate, Tenascin, and Hyaluronan, and Their Association with Disease Outcome in Node-Negative Breast Cancer

Suwiwat

Ricciardelli

Tammi

et al. 2004

Clinical Cancer Research

136

View full text Add to dashboard Cite

Purpose:The purpose is to determine whether the levels of expression of extracellular matrix components in peritumoral stroma are predictive of disease outcome for women with node-negative breast cancer.Experimental Design: Tumor tissue from 86 patients with node-negative breast cancer was examined by immunohistochemical staining for the expression of versican, chondroitin sulfate (CS), tenascin, and hyaluronan (HA). With the exception of HA, the expression of the extracellular matrix components was measured by video image analysis. Statistical correlation of the immunohistochemical data with clinicopathological characteristics and disease outcome was performed.Results: All of the extracellular matrix components were present in the peritumoral stroma of the entire study cohort. In contrast, immunoreactivity within the cancer cell was observed in 82% of tumors for HA, 12% for CS, and 4% for tenascin; no immunostaining of cancer cells for versican was observed for any of the tumors. Cox regression and Kaplan-Meier analyses indicated that elevated expression of stromal versican predicted increased risk and rate of relapse in this cohort. Elevated expression of tenascin was predictive of increased risk and rate of death only. Although neither CS nor HA were predictive of disease outcome in this cohort, tumor size was predictive of increased risk and rate of both relapse and survival.Conclusions: Elevated expression within peritumoral stromal matrix of versican and tenascin was predictive of relapse-free and overall survival, respectively, in women with node-negative breast cancer.

show abstract

Gains and losses of CD44 expression during breast carcinogenesis and tumour progression

Abstract: Qualitative and quantitative changes of CD44 expression are implicated in early stages of breast carcinogenesis. The restricted neo-expression of certain CD44 isoforms in breast neoplasias suggests that CD44 might be a potential target for future antibody-based tumour therapy.

Cited by 63 publications

References 34 publications

Different proliferative activity of the glandular and myoepithelial lineages in benign proliferative and early malignant breast diseases

Different proliferative activity of the glandular and myoepithelial lineages in benign proliferative and early malignant breast diseases

Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer

Expression of Extracellular Matrix Components Versican, Chondroitin Sulfate, Tenascin, and Hyaluronan, and Their Association with Disease Outcome in Node-Negative Breast Cancer

Contact Info

Product

Resources

About